Recombinant adeno-associated viruses (AAVs) have emerged as promising gene delivery
vehicles resulting in three US Food and Drug Administration (FDA) and one European …

Recombinant adeno-associated virus (rAAV) vectors are one of the most promising in vivo
gene delivery tools. Several features make rAAV vectors an ideal platform for gene transfer …

Gene therapy with adeno-associated virus (AAV) vectors has demonstrated safety and long-
term efficacy in a number of trials across target organs, including eye, liver, skeletal muscle …

Recombinant vectors based on adeno-associated virus (AAV) have been shown to stably
express many genes in vivo without mounting immune responses to vectors or transgenes …

The field of gene therapy has made considerable progress over the past several years.
Adeno-associated virus (AAV) vectors have emerged as promising and attractive tools for in …

Adeno-associated viral (AAV) vectors have emerged as the leading gene delivery platform
for gene therapy and vaccination. Three AAV-based gene therapy drugs, Glybera …

Over the past decade, vectors derived from adeno-associated virus (AAV) have established
themselves as a powerful tool for in vivo gene transfer, allowing long-lasting and safe …

One of the biggest challenges in optimizing viral vectors for gene therapy relates to the
immune response of the host. Adeno-associated virus (AAV) vectors are associated with low …

Adeno-associated virus (AAV) vectors are one of the most efficient in vivo gene delivery
platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to …

Immune responses in gene therapy with adeno-associated virus (AAV) vectors have been
the object of almost two decades of study. Although preclinical models helped to define and …